6-12-18 SmallCapVoice Interview with Briacell Therapeutics Corp. (BCTXF)

Dr. Bill Williams, BriaCell’s President & CEO, called in to SmallCapVoice.com, Inc. to discuss the importance of the Company’s recent clinical findings as published in the American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings. ASCO’s Annual Meeting represents the world’s largest gathering of oncology physicians, biotechnology executives, researchers, and investment analysts to discuss breakthrough clinical research and therapeutics in the field. Additionally, Dr. Williams discusses the significance of the novel mechanism of action of BriaCell’s lead product candidate, Bria-IMT™ which has been recently published in the journal of Frontiers in Immunology, the 5th most cited journal in Immunology.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.